bpc-157 human clinical trials safety adverse events The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity bpc-157 safety adverse events case

NAD also plays a key role in DNA repair, healthy gene expression, and cell signaling

Timestamps 00:00 Cold open: 200 years of menopause medicine 03:23 Welcome and roadmap 04:20 The HPG axis, follicles, and the FSH lag 09:11 STRAW+10 staging and the timing of perimenopause 13:47 Austin: the 49-year-old with a hormone panel 20:00 Loraine: the OB-GYN workup 28:00 Symptom attribution: what menopause actually causes 33:46 Austin: the all-estrogen patient 37:58 VMS duration and the KNDy mechanism (Avis, SKYLIGHT) 43:53 Austin: who actually gets fezolinetant 47:22 The WHI 24-year correction (Manson, Chlebowski, Boardman) 01:00:15 Modern prescribing today 01:06:52 Where the menopause-content space gets it right and wrong 01:11:50 Testosterone, compounded bioidenticals, and DUTCH panels 01:24:13 Takeaways What we cover The HPG axis and the estrogen shield: what is happening across the 35-year reproductive era and what changes at perimenopause

He was considering adding 0.5mg oral BPC-157 on top, but ended up sticking to the dosage after some discussion within the peptide community

Supplied in lyophilized powder form to help preserve stability throughout transport and storage

Free shipping on US orders over $100

This suggests a very good safety and tolerability profile indistinguishable from placebo in those trial settings